A funding round brought in $6.5 million for Aspen Neuroscience, a newly launched biotech that is developing an autologous neuron replacement for patients with Parkinson's disease. Aspen will need to raise additional capital via a Series A funding round to advance its lead candidates through midstage trials, though.
New biotech raises $6.5M to advance stem cell therapy for Parkinson's
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.